Compare JFIN & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | CRBP |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.7M | 168.3M |
| IPO Year | 2018 | 2014 |
| Metric | JFIN | CRBP |
|---|---|---|
| Price | $2.16 | $8.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 62.6K | ★ 275.0K |
| Earning Date | 06-03-2026 | 05-08-2026 |
| Dividend Yield | ★ 17.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $2.12 | $7.12 |
| 52 Week High | $14.70 | $20.56 |
| Indicator | JFIN | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 22.96 | 45.94 |
| Support Level | N/A | $7.86 |
| Resistance Level | $4.54 | $9.73 |
| Average True Range (ATR) | 0.14 | 0.47 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 7.68 | 25.00 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.